An investigation on production routes of U-230 radioisotope used in targeted alpha therapy by different level density models

Basit Öğe Kaydı
dc.contributor.authorÖzdoğan, Hasan
dc.contributor.authorŞekerci, Mert
dc.contributor.authorCinoğlu Karaca, Merve
dc.contributor.authorOkutan, Murat
dc.contributor.authorDemir, Bayram
dc.contributor.authorKaplan, Abdullah
dc.date.accessioned2023-03-09T09:16:13Z
dc.date.available2023-03-09T09:16:13Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Nükleer Tıp Ana Bilim Dalı
dc.description.abstractTargeted alpha therapy (TAT) is an attractive therapeutic option in patients with multiple micrometastases. It offers many advantages, including easy administration, the ability to treat multiple lesions simultaneously and the possibility of combination with other therapeutic approaches for improved efficacy. The aim of this study is to investigate the optimum production route of U-230, which is a promising TAT isotope, in cyclotrons. For this, Pa-231(p, 2n)U-230, Pa-231(d, 3n)U-230, Th-232(p, 3n)Pa-230, and Th-232(d, 4n)Pa-230, reactions cross-sections, total activity and reaction yield have been calculated by using different level density models of TALYS 1.95 code. It is possible to produce an U-230 activity of 53.491 mCi via on Pa-231(p, 2n)U-230 direct route with 12.8 MeV protons at 1 mA current for 24 h. After a 28 days waiting period required for undesirable product (U-230) activity to decrease sufficiently, this activity decreases to 21.4 mCi and by considering the average dose per patient as 0.5 mCi, these activities are enough for 43 patients. Besides, Pa-231 is already the target material in this direct production route and Pa-231 obtained from undesirable product U-231 can be stored and processed for re-use as the target material. In this way, a significant amount of source material can be recovered.
dc.identifier.citationÖzdoğan, H., Şekerci, M., Cinoğlu Karaca, M., Okutan, M., Demir, B. ve Kaplan, A. (2022). An investigation on production routes of U-230 radioisotope used in targeted alpha therapy by different level density models. Moscow University Physics Bulletin, 77(6), 878-885. https://dx.doi.org/10.3103/S0027134922060170
dc.identifier.doi10.3103/S0027134922060170
dc.identifier.endpage885
dc.identifier.issn0027-1349
dc.identifier.issn1934-8460
dc.identifier.issue6
dc.identifier.startpage878
dc.identifier.urihttps://dx.doi.org/10.3103/S0027134922060170
dc.identifier.urihttps://hdl.handle.net/20.500.12511/10591
dc.identifier.volume77
dc.identifier.wos000935207100011en_US
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.institutionauthorCinoğlu Karaca, Merve
dc.language.isoen
dc.publisherPleiades Publishing Inc
dc.relation.ispartofMoscow University Physics Bulletinen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectU-230
dc.subjectAlpha Therapy
dc.subjectDensity Models
dc.subjectProduction Routes
dc.titleAn investigation on production routes of U-230 radioisotope used in targeted alpha therapy by different level density models
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu